This study tests a new drug, WTX-330, for people with serious tumors or a blood cancer called non-Hodgkin lymphoma. The drug is a special version of IL-12, which is a type of medicine that helps the immune system fight cancer. The study is in its first phase, meaning it's mostly to check if the drug is safe and how well it works. Patients in the study must have tried all other usual treatments that didn't work. There are two parts to the study: one for people who have previously used a type of cancer drug called a checkpoint inhibitor, and the other for those who haven't.
- Study Length: The length of participation is based on individual responses and tolerance to the treatment.
- Treatment: WTX-330 given alone, no other medication combined.
- Risks: There may be risks like side effects, but these will be monitored closely by doctors.
How understandable was the trial content above?
Hard to understand
Easy to understand